These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

186 related articles for article (PubMed ID: 18503998)

  • 1. Study design and endpoints in graft-versus-host disease.
    Martin PJ
    Best Pract Res Clin Haematol; 2008 Jun; 21(2):357-72. PubMed ID: 18503998
    [TBL] [Abstract][Full Text] [Related]  

  • 2. National Institutes of Health Consensus Development Project on Criteria for Clinical Trials in Chronic Graft-versus-Host Disease: VI. Design of Clinical Trials Working Group report.
    Martin PJ; Weisdorf D; Przepiorka D; Hirschfeld S; Farrell A; Rizzo JD; Foley R; Socie G; Carter S; Couriel D; Schultz KR; Flowers ME; Filipovich AH; Saliba R; Vogelsang GB; Pavletic SZ; Lee SJ;
    Biol Blood Marrow Transplant; 2006 May; 12(5):491-505. PubMed ID: 16635784
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Folic acid supplementation and malaria susceptibility and severity among people taking antifolate antimalarial drugs in endemic areas.
    Crider K; Williams J; Qi YP; Gutman J; Yeung L; Mai C; Finkelstain J; Mehta S; Pons-Duran C; Menéndez C; Moraleda C; Rogers L; Daniels K; Green P
    Cochrane Database Syst Rev; 2022 Feb; 2(2022):. PubMed ID: 36321557
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Blood and Marrow Transplant Clinical Trials Network Report on the Development of Novel Endpoints and Selection of Promising Approaches for Graft-versus-Host Disease Prevention Trials.
    Pasquini MC; Logan B; Jones RJ; Alousi AM; Appelbaum FR; Bolaños-Meade J; Flowers MED; Giralt S; Horowitz MM; Jacobsohn D; Koreth J; Levine JE; Luznik L; Maziarz R; Mendizabal A; Pavletic S; Perales MA; Porter D; Reshef R; Weisdorf D; Antin JH
    Biol Blood Marrow Transplant; 2018 Jun; 24(6):1274-1280. PubMed ID: 29325830
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Rationale and design of the chronic GVHD cohort study: improving outcomes assessment in chronic GVHD.
    Chronic GVHD Consortium
    Biol Blood Marrow Transplant; 2011 Aug; 17(8):1114-20. PubMed ID: 21664473
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Patient-reported outcomes for acute graft-versus-host disease prevention and treatment trials.
    Lee SJ; Williams LA
    Biol Blood Marrow Transplant; 2010 Mar; 16(3):295-300. PubMed ID: 19747556
    [TBL] [Abstract][Full Text] [Related]  

  • 7. National Institutes of Health Consensus Development Project on Criteria for Clinical Trials in Chronic Graft-versus-Host Disease: VI. The 2014 Clinical Trial Design Working Group Report.
    Martin PJ; Lee SJ; Przepiorka D; Horowitz MM; Koreth J; Vogelsang GB; Walker I; Carpenter PA; Griffith LM; Akpek G; Mohty M; Wolff D; Pavletic SZ; Cutler CS
    Biol Blood Marrow Transplant; 2015 Aug; 21(8):1343-59. PubMed ID: 25985921
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Measuring therapeutic response in chronic graft-versus-host disease. National Institutes of Health consensus development project on criteria for clinical trials in chronic graft-versus-host disease: IV. The 2014 Response Criteria Working Group report.
    Lee SJ; Wolff D; Kitko C; Koreth J; Inamoto Y; Jagasia M; Pidala J; Olivieri A; Martin PJ; Przepiorka D; Pusic I; Dignan F; Mitchell SA; Lawitschka A; Jacobsohn D; Hall AM; Flowers ME; Schultz KR; Vogelsang G; Pavletic S
    Biol Blood Marrow Transplant; 2015 Jun; 21(6):984-99. PubMed ID: 25796139
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Endpoints for clinical trials testing treatment of acute graft-versus-host disease: a joint statement.
    Martin PJ; Bachier CR; Klingemann HG; McCarthy PL; Szabolcs P; Uberti JP; Schuster MW; Weisdorf D; Chao NJ; Kebriaei P; Shpall EJ; Macmillan ML; Soiffer RJ
    Biol Blood Marrow Transplant; 2009 Jul; 15(7):777-84. PubMed ID: 19539208
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Polyclonal anti-thymocyte globulins for the prophylaxis of graft-versus-host disease after allogeneic stem cell or bone marrow transplantation in adults.
    Theurich S; Fischmann H; Shimabukuro-Vornhagen A; Chemnitz JM; Holtick U; Scheid C; Skoetz N; von Bergwelt-Baildon M
    Cochrane Database Syst Rev; 2012 Sep; (9):CD009159. PubMed ID: 22972135
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Ruxolitinib in GvHD (RIG) study: a multicenter, randomized phase 2 trial to determine the response rate of Ruxolitinib and best available treatment (BAT) versus BAT in steroid-refractory acute graft-versus-host disease (aGvHD) (NCT02396628).
    von Bubnoff N; Ihorst G; Grishina O; Röthling N; Bertz H; Duyster J; Finke J; Zeiser R
    BMC Cancer; 2018 Nov; 18(1):1132. PubMed ID: 30453910
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Safety and Efficacy of Imatinib for Hospitalized Adults with COVID-19: A structured summary of a study protocol for a randomised controlled trial.
    Emadi A; Chua JV; Talwani R; Bentzen SM; Baddley J
    Trials; 2020 Oct; 21(1):897. PubMed ID: 33115543
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Mesenchymal stromal cells as treatment or prophylaxis for acute or chronic graft-versus-host disease in haematopoietic stem cell transplant (HSCT) recipients with a haematological condition.
    Fisher SA; Cutler A; Doree C; Brunskill SJ; Stanworth SJ; Navarrete C; Girdlestone J
    Cochrane Database Syst Rev; 2019 Jan; 1(1):CD009768. PubMed ID: 30697701
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Emerging therapies for graft-versus-host disease.
    Jacobsohn DA
    Expert Opin Emerg Drugs; 2003 Nov; 8(2):323-38. PubMed ID: 14661992
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Mycophenolate mofetil for the prevention and treatment of graft-versus-host disease following stem cell transplantation: preliminary findings.
    Vogelsang GB; Arai S
    Bone Marrow Transplant; 2001 Jun; 27(12):1255-62. PubMed ID: 11548843
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Evaluation of thalidomide for treatment or prevention of chronic graft-versus-host disease.
    Flowers ME; Martin PJ
    Leuk Lymphoma; 2003 Jul; 44(7):1141-6. PubMed ID: 12916865
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Graft-versus-host disease: why have we not made more progress?
    Jaglowski SM; Devine SM
    Curr Opin Hematol; 2014 Mar; 21(2):141-7. PubMed ID: 24468835
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Graft-versus-host disease prophylaxis: Pathophysiology-based review on current approaches and future directions.
    Martinez-Cibrian N; Zeiser R; Perez-Simon JA
    Blood Rev; 2021 Jul; 48():100792. PubMed ID: 33386151
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Measuring therapeutic response in chronic graft-versus-host disease: National Institutes of Health Consensus Development Project on Criteria for Clinical Trials in Chronic Graft-versus-Host Disease: IV. Response Criteria Working Group report.
    Pavletic SZ; Martin P; Lee SJ; Mitchell S; Jacobsohn D; Cowen EW; Turner ML; Akpek G; Gilman A; McDonald G; Schubert M; Berger A; Bross P; Chien JW; Couriel D; Dunn JP; Fall-Dickson J; Farrell A; Flowers ME; Greinix H; Hirschfeld S; Gerber L; Kim S; Knobler R; Lachenbruch PA; Miller FW; Mittleman B; Papadopoulos E; Parsons SK; Przepiorka D; Robinson M; Ward M; Reeve B; Rider LG; Shulman H; Schultz KR; Weisdorf D; Vogelsang GB;
    Biol Blood Marrow Transplant; 2006 Mar; 12(3):252-66. PubMed ID: 16503494
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Correlation of Patient-Reported Outcomes with Clinical Organ Responses: Data from the Belumosudil Chronic Graft-versus-Host Disease Studies.
    Lee SJ; Cutler C; Blazar BR; Tu A; Yang Z; Pavletic SZ
    Transplant Cell Ther; 2022 Oct; 28(10):700.e1-700.e6. PubMed ID: 35781099
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 10.